Stephen Reed
Interventional Cardiology · Fort Wayne, INNPI 1053381764
Payments from drug & device makers
Across 95 payments — averaging $27.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$740
- Abbott$680
- AstraZeneca$479
- Angiodynamics, Inc.$182
- Biotronik Inc.$81
- Shockwave Medical, Inc$71
- plus $384 from 14 others
What the payments were for
- Travel & lodging$55621%
- Food & beverage$2,03778%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 7 | $740 |
| Abbott | 23 | $680 |
| AstraZeneca | 27 | $479 |
| Angiodynamics, Inc. | 7 | $182 |
| Biotronik Inc. | 3 | $81 |
| Shockwave Medical, Inc | 3 | $71 |
| Novartis | 3 | $61 |
| Merck | 3 | $51 |
| Cardiovascular Systems Inc. | 4 | $42 |
| Boston Scientific | 1 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Johnson & Johnson | 2 | $28 |
| Terumo Medical Corporation | 1 | $27 |
| Regeneron Healthcare Solutions, Inc. | 2 | $26 |
| Werfen USA LLC | 1 | $20 |
| Amgen | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Pfizer | 1 | $13 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,617 in reported general payments places this provider in the 20th percentile of 170 interventional cardiology providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 45 | $58,625 |
| XareltoRivaroxaban | 13 | $14,701 |
| ClopidogrelClopidogrel Bisulfate | 44 | $556 |
| Pravastatin Sodium | 14 | $388 |
| Carvedilol | 36 | $312 |
| Atorvastatin Calcium | 45 | $292 |
| Metoprolol Succinate | 43 | $258 |
| Rosuvastatin Calcium | 37 | $203 |
| Metoprolol Tartrate | 26 | $153 |
| Ezetimibe | 12 | $152 |
| Losartan Potassium | 19 | $145 |
| Amlodipine Besylate | 23 | $55 |
| Lisinopril | 15 | $36 |
| Simvastatin | 11 | $30 |
| Furosemide | 11 | $18 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $13 | $58,62545 claims |
| Johnson & JohnsonXarelto | $28 | $14,70113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 170 interventional cardiology providers in Indiana.
Other interventional cardiology in Fort Wayne
- Muzammil MusaniFort Wayne$184K
- Roy RobertsonFort Wayne$148K
- Peter ChailleFort Wayne$143K
- Vijay ChilakamarriFort Wayne$54K
- Christopher SmitsonFort Wayne$24K
- James HermillerIndianapolis$2.8M
- Jithendra ChoudaryRichmond$1.6M
- Jeffrey BreallIndianapolis$955K
- Samer AbbasEast Chicago$625K
- Jarrod FrizzellEvansville$559K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.